5hf3: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Crystal structure of C-terminal modified Tau peptide-hybrid 201D with 14-3-3sigma== | ==Crystal structure of C-terminal modified Tau peptide-hybrid 201D with 14-3-3sigma== | ||
<StructureSection load='5hf3' size='340' side='right' caption='[[5hf3]], [[Resolution|resolution]] 1.80Å' scene=''> | <StructureSection load='5hf3' size='340' side='right' caption='[[5hf3]], [[Resolution|resolution]] 1.80Å' scene=''> | ||
| Line 5: | Line 6: | ||
</td></tr><tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=60H:(2~{S})-2-(DIPHENYLMETHYL)PYRROLIDINE'>60H</scene>, <scene name='pdbligand=ACE:ACETYL+GROUP'>ACE</scene>, <scene name='pdbligand=CSO:S-HYDROXYCYSTEINE'>CSO</scene>, <scene name='pdbligand=SEP:PHOSPHOSERINE'>SEP</scene></td></tr> | </td></tr><tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=60H:(2~{S})-2-(DIPHENYLMETHYL)PYRROLIDINE'>60H</scene>, <scene name='pdbligand=ACE:ACETYL+GROUP'>ACE</scene>, <scene name='pdbligand=CSO:S-HYDROXYCYSTEINE'>CSO</scene>, <scene name='pdbligand=SEP:PHOSPHOSERINE'>SEP</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4y3b|4y3b]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4y3b|4y3b]]</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5hf3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5hf3 OCA], [http://pdbe.org/5hf3 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5hf3 RCSB], [http://www.ebi.ac.uk/pdbsum/5hf3 PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5hf3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5hf3 OCA], [http://pdbe.org/5hf3 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5hf3 RCSB], [http://www.ebi.ac.uk/pdbsum/5hf3 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5hf3 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
| Line 18: | Line 19: | ||
</div> | </div> | ||
<div class="pdbe-citations 5hf3" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 5hf3" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[14-3-3 protein|14-3-3 protein]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 09:57, 6 October 2017
Crystal structure of C-terminal modified Tau peptide-hybrid 201D with 14-3-3sigmaCrystal structure of C-terminal modified Tau peptide-hybrid 201D with 14-3-3sigma
Structural highlights
Function[1433S_HUMAN] Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. When bound to KRT17, regulates protein synthesis and epithelial cell growth by stimulating Akt/mTOR pathway (By similarity). p53-regulated inhibitor of G2/M progression. Publication Abstract from PubMedThe discovery of novel protein-protein interaction (PPI) modulators represents one of the great molecular challenges of the modern era. PPIs can be modulated by either inhibitor or stabilizer compounds, which target different though proximal regions of the protein interface. In principle, protein-stabilizer complexes can guide the design of PPI inhibitors (and vice versa). In the present work, we combine X-ray crystallographic data from both stabilizer and inhibitor co-crystal complexes of the adapter protein 14-3-3 to characterize, down to the atomic scale, inhibitors of the 14-3-3/Tau PPI, a potential drug target to treat Alzheimer's disease. The most potent compound notably inhibited the binding of phosphorylated full-length Tau to 14-3-3 according to NMR spectroscopy studies. Our work sets a precedent for the rational design of PPI inhibitors guided by PPI stabilizer-protein complexes while potentially enabling access to new synthetically tractable stabilizers of 14-3-3 and other PPIs. Stabilizer-Guided Inhibition of Protein-Protein Interactions.,Milroy LG, Bartel M, Henen MA, Leysen S, Adriaans JM, Brunsveld L, Landrieu I, Ottmann C Angew Chem Int Ed Engl. 2015 Nov 5. doi: 10.1002/anie.201507976. PMID:26537010[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||